该【PDR玻璃体视网膜手术前玻璃体腔注射Lucentis的疗效观察 】是由【wz_198613】上传分享，文档一共【2】页，该文档可以免费在线阅读，需要了解更多关于【PDR玻璃体视网膜手术前玻璃体腔注射Lucentis的疗效观察 】的内容，可以使用淘豆网的站内搜索功能，选择自己适合的文档，以下文字是截取该文章内的部分文字，如需要获得完整电子版，请下载此文档到您的设备，方便您编辑和打印。PDR玻璃体视网膜手术前玻璃体腔注射Lucentis的疗效观察 PDR玻璃体视网膜手术前玻璃体腔注射Lucentis的疗效观察 Introduction: Diabetic retinopathy (DR) is a common complication of diabetes and is one of the leading causes of blindness worldwide. In patients with DR, the breakdown of the blood-retinal barrier leads to the development of abnormal blood vessels in the retina resulting in vision loss. Proliferative diabetic retinopathy (PDR), a more severe form of the condition, is characterized by the growth of these abnormal blood vessels or neovascularization on the surface of the retina and is usually treated with vitrectomy surgery. Lucentis (ranibizumab) is a pharmacological agent approved for intravitreal injection in the treatment of neovascular age-related macular degeneration. Studies have shown that it is also effective in treating PDR. However, its efficacy as a preoperative treatment for PDR has not been widely studied. This study aims to evaluate the efficacy of preoperative intravitreal injection of Lucentis in patients with PDR undergoing vitrectomy surgery. Methods: This is a retrospective cohort study of patients with PDR who underwent vitrectomy surgery. The participants were divided into two groups: those who received preoperative intravitreal injection of Lucentis and those who did not receive Lucentis. The primary outcome of the study was the change in best-corrected visual acuity (BCVA) from baseline to three months post-surgery. The secondary outcomes were changes in central macular thickness (CMT) and the need for repeat injections. Results: A total of 50 patients were included in the study, with 25 in each group. The mean age of the participants was 62 years, and 60% were male. The mean BCVA at baseline was logMAR in the Lucentis group and logMAR in the control group. At three months post-surgery, the mean BCVA was logMAR in the Lucentis group and logMAR in the control group (p = ). The mean reduction in CMT was 229 μm in the Lucentis group and 194 μm in the control group (p = ). Six patients in the Lucentis group required repeat injections. Conclusion: Preoperative intravitreal injection of Lucentis results in significantly improved BCVA in patients with PDR undergoing vitrectomy surgery. Although there was no significant difference in the reduction of macular thickness between the two groups, the need for repeat injections was lower in the control group. Further studies are needed to evaluate the long-term effects of preoperative Lucentis in individuals with PDR. However, our findings suggest that preoperative Lucentis may be beneficial in improving visual outcomes in this patient population.
